24 mRNA / RNA Manufacturing CDMOs

What is mRNA / RNA Manufacturing and when do you need it?

mRNA / RNA Manufacturing is how an RNA sequence on a screen becomes physical drug substance you can dose. The core of it is in vitro transcription (IVT): an RNA polymerase reads a linearized DNA template and synthesizes the RNA strand, after which the molecule is capped (co-transcriptionally with a cap analog, or enzymatically), given a poly-A tail, and then purified to strip out the template DNA, double-stranded RNA byproducts, residual NTPs, and enzyme. The same backbone process covers conventional mRNA, self-amplifying RNA (saRNA), circular RNA, and increasingly the chemically modified constructs that use N1-methylpseudouridine in place of uridine to dial down innate immune activation.

You reach for an RNA CDMO at a specific point: you have a validated sequence and a plasmid (or a PCR template), and you now need material that is documented, release-tested, and made to a defined quality grade. That can be research-grade RNA for a tox study, then a step up to GMP drug substance for an IND and first-in-human dosing. RNA is one of the faster modalities to manufacture, which is exactly why it carried the COVID vaccines, but the speed assumes the upstream pieces are ready. The linearized plasmid template is on the critical path, the cap strategy is locked, and the analytical methods to prove integrity and purity exist.

Two scope boundaries are worth drawing before you talk to a vendor. First, naked mRNA is fragile and almost never the final product, so most programs pair RNA drug substance with LNP encapsulation (lipid nanoparticle formulation) as the drug-product step. Some CDMOs do both under one roof; others stop at purified RNA and hand off to a separate fill-finish or LNP partner. Second, the DNA template itself (plasmid DNA manufacturing) is an upstream service in its own right. Knowing where one vendor's scope ends and the next begins is most of what keeps an RNA program from stalling between suppliers.

What does an mRNA / RNA Manufacturing CDMO actually do?

Walk the process and you can see what you are actually buying. It starts with the template: a plasmid is linearized with a restriction enzyme (or amplified by PCR) to give the polymerase a clean stop point. The IVT reaction then runs in a bioreactor or large vessel with the polymerase, the four nucleotides (sometimes including modified bases), and a cap analog if capping is co-transcriptional. Downstream processing is where a lot of the real know-how sits: DNase digestion to clear the template, then a purification train, often tangential flow filtration plus a chromatography step (oligo-dT affinity capture for the poly-A tail, or reversed-phase or anion-exchange) to remove dsRNA and process impurities that drive reactogenicity.

The other half of the job is proving what you made. RNA analytics are their own discipline: capillary gel electrophoresis or fragment analysis for integrity and intactness, a capping efficiency assay (often by LC-MS), poly-A tail length characterization, dsRNA quantitation by immunoblot or ELISA, residual DNA template and residual protein testing, endotoxin, and sequence confirmation. A capable CDMO will have these methods qualified or validated, not improvised per batch. When you compare quotes, the analytical package and the quality grade (research, GMP-like, full GMP) are usually where the real cost and timeline differences live, more than the IVT reaction itself.

Beyond the wet work, an RNA CDMO supplies the documentation and regulatory scaffolding that makes the material usable: batch records, certificates of analysis, a defined specification, stability data, and the CMC sections that feed your IND. Many also offer tech transfer (taking your process or a licensed process into their facility) and scale-up from a few milligrams for early studies to gram and multi-gram batches for clinical supply.

How do you choose an mRNA / RNA Manufacturing CDMO?

The honest filter is fit to your construct and your stage, not the size of the facility. A CDMO that runs vaccine-scale mRNA campaigns may be over-built for a rare-disease program that needs a few grams, and a shop that is strong on standard mRNA may be a beginner at self-amplifying or circular RNA. Score two or three vendors against the same written scope (sequence type, quantity, quality grade, cap strategy, whether LNP is included), and weigh the analytical and regulatory track record at least as heavily as the per-gram price.

• Quality and GxP status: confirm the actual grade on offer (research, non-GMP engineering, or full GMP under 21 CFR Part 211 / EU GMP), recent regulatory inspection history, and whether their RNA-specific analytical methods (integrity, capping efficiency, dsRNA, residual DNA) are qualified or validated.
• Capacity and lead time: scale you can grow into (milligram tox batches through gram-scale clinical supply), realistic slot availability, and where the critical path sits, usually template linearization, raw-material and cap-analog lead times, and method readiness rather than the IVT step itself.
• Modality and indication fit: real experience with your construct (standard mRNA, saRNA, circular RNA, modified-nucleotide chemistry) and your application (vaccine, protein-replacement, in vivo editing), since the purification and analytics differ across them.
• LNP and drug-product scope: whether they encapsulate to LNP and fill-finish in-house or stop at purified drug substance, plus how the plasmid template (your DNA starting material) is sourced and qualified, so you know exactly where handoffs occur.
• Region and regulatory track record: where the site sits, which agencies they have filed with (FDA, EMA, others), and whether they can support the markets you intend to file in, including raw-material traceability and supply security.
• Data quality and transparency: clear batch records, certificates of analysis against a defined specification, stability data, and straight reporting of out-of-spec or failed lots, not just a headline yield.
• IP and confidentiality: who owns process improvements made on your program, how your sequence and template are protected, freedom-to-operate on any licensed capping or platform technology, and clean tech-transfer terms if you move the process later.